The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein
Antigen designed to support immunoassay and vaccine development applications Oxford, UK, XX December 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and...
The Native Antigen Company introduces new range of influenza antigens
Season-specific Haemagglutinin and Neuraminidase antigens will support vaccine and diagnostic reformulation programmes New range developed to cover 2023 southern hemisphere flu season Oxford, UK, 14 November 2022: The Native Antigen Company (part of LGC Clinical...
The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant
New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases Oxford, UK, 02 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables...